EP0938334A4 - Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes - Google Patents

Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes

Info

Publication number
EP0938334A4
EP0938334A4 EP97936109A EP97936109A EP0938334A4 EP 0938334 A4 EP0938334 A4 EP 0938334A4 EP 97936109 A EP97936109 A EP 97936109A EP 97936109 A EP97936109 A EP 97936109A EP 0938334 A4 EP0938334 A4 EP 0938334A4
Authority
EP
European Patent Office
Prior art keywords
improved method
immune cell
cell mediated
systemic diseases
treating immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97936109A
Other languages
German (de)
English (en)
Other versions
EP0938334A1 (fr
Inventor
Charles Baldwin Davis
Peter John Bugelski
Brian Richard Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0938334A1 publication Critical patent/EP0938334A1/fr
Publication of EP0938334A4 publication Critical patent/EP0938334A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP97936109A 1996-07-26 1997-07-25 Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes Withdrawn EP0938334A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2247296P 1996-07-26 1996-07-26
US22472P 1996-07-26
PCT/US1997/012600 WO1998004281A1 (fr) 1996-07-26 1997-07-25 Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes

Publications (2)

Publication Number Publication Date
EP0938334A1 EP0938334A1 (fr) 1999-09-01
EP0938334A4 true EP0938334A4 (fr) 2004-12-15

Family

ID=21809771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97936109A Withdrawn EP0938334A4 (fr) 1996-07-26 1997-07-25 Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes

Country Status (3)

Country Link
EP (1) EP0938334A4 (fr)
JP (1) JP2000516594A (fr)
WO (1) WO1998004281A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303703B6 (cs) * 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
CA2379274A1 (fr) * 1999-07-12 2001-01-18 Genentech, Inc. Blocage d'une reponse immunitaire a un antigene etranger au moyen d'un antagoniste de liaison a cd20
WO2002022212A2 (fr) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
CA2868614A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
AU2004252067B2 (en) 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
ES2360369T5 (es) * 2004-12-23 2021-12-13 Hoffmann La Roche Detección de un anticuerpo terapéutico en un animal de experimentación
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
WO2007047539A2 (fr) * 2005-10-14 2007-04-26 Medtronic, Inc. Administration localisee au systeme lymphatique
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
RU2603284C2 (ru) 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017184880A1 (fr) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. Procédé de remplissage d'un récipient sans espace libre
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
WO2018183041A1 (fr) 2017-03-27 2018-10-04 Immunomedics, Inc. Traitement de cancer du sein triple négatif exprimant la trop-2 avec du sacmuzumab govitécan et un inhibiteur de rad51
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009351A1 (fr) * 1995-09-06 1997-03-13 Idec Pharmaceuticals Corporation Anticorps anti-cd4 recombinants pour therapie humaine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009351A1 (fr) * 1995-09-06 1997-03-13 Idec Pharmaceuticals Corporation Anticorps anti-cd4 recombinants pour therapie humaine

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BATA-CSORGO Z ET AL: "Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. JUL 1995, vol. 105, no. 1 Suppl, July 1995 (1995-07-01), pages 89S - 94S, XP009034211, ISSN: 0022-202X *
EMMRICH F ET AL: "An anti-CD4 antibody for treatment of chronic inflammatory arthritis.", AGENTS AND ACTIONS. SUPPLEMENTS. 1991, vol. 32, 1991, pages 165 - 170, XP001182725, ISSN: 0379-0363 *
GAVETT S H ET AL: "Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. JUN 1994, vol. 10, no. 6, June 1994 (1994-06-01), pages 587 - 593, XP009034204, ISSN: 1044-1549 *
KAINE J ET AL: "RESULTS OF A MULTI-DOSE PROTOCOL 7002 USING AN IMMUNOMODULATING NON-DEPLETING PRIMATIZEDTM ANTI-CD4 MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 38, no. 9, SUPPL, 21 November 1995 (1995-11-21), pages S185,AN195, XP001095999, ISSN: 0004-3591 *
MORELAND L W ET AL: "TREATING RHEUMATOID ARTHRITIS WITH A NON-DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, 5 May 1995 (1995-05-05), pages 362A, XP001106168, ISSN: 1081-5589 *
See also references of WO9804281A1 *
THIVOLET J ET AL: "Immunointervention in psoriasis with anti-CD4 antibodies.", INTERNATIONAL JOURNAL OF DERMATOLOGY. MAY 1994, vol. 33, no. 5, May 1994 (1994-05-01), pages 327 - 332, XP009034206, ISSN: 0011-9059 *
YOCUM D E ET AL: "CLINICAL AND IMMUNOPHARMACOLOGIC EFFECTS OF PRIMATIZEDTM IDEC-CE9.1, AN ANTI-CD4 MONOCLONALANTIBODY IN A PHASE I TRIAL IN ACTIVE RHEUMATOID ARTHRITIS", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 43, no. SUPPL 2, April 1995 (1995-04-01), pages 253A, XP001095992, ISSN: 1081-5589 *

Also Published As

Publication number Publication date
WO1998004281A1 (fr) 1998-02-05
JP2000516594A (ja) 2000-12-12
EP0938334A1 (fr) 1999-09-01

Similar Documents

Publication Publication Date Title
EP0938334A4 (fr) Methode amelioree de traitement de maladies de l'organisme induites par des cellules immunes
PL327827A1 (en) Method of retarding the skin photoageing process
IL127912A0 (en) Method of activating dendritic cells
GB2314737B (en) Method of enabling handoff
PL332375A1 (en) Novel phytases and method of obtaining them
GB9620892D0 (en) Methods of treating RAF mediated diseases
GB9617780D0 (en) Method of treatment
EP1005700A4 (fr) Appareil et procede perfectionnes pour fabriquer des claviers numeriques
EP0735054A3 (fr) Méthode de psot-traitement de polyoléfines modifiées
GB9715295D0 (en) Novel method of treatment
EP0933803A4 (fr) Procede de traitement au plasma
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
EG21026A (en) Method of charging ore
IL127182A0 (en) Method of improving skin condition
HUP9802834A3 (en) Preparations for the treatment of t cell mediated autoimmune diseases
GB9715298D0 (en) Novel method of treatment
MD798F1 (en) Method of the mamma cancer treatment
GB9715306D0 (en) Novel method of treatment
GB2324233B (en) Electric heater and method of manufacture
GB9618341D0 (en) Method of treatment
GB9623286D0 (en) Electrodes and methods of making them
GB9507825D0 (en) Method of treatment
GB9602867D0 (en) Methods of treating raf mediated diseases
GB9407335D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20041022

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050111